ANNEX 2

SUMMARY: Third health programme — 2020 work programme

Annex 1 sets out priorities and actions, including the allocation of resources, for the implementation in 2020 of the third programme of the Union’s action in the field of health (2014-2020), established under Regulation (EU) No 282/2014 (‘the Programme Regulation’).

Article 11 of the Programme Regulation requires the Commission to adopt, by means of implementing acts, annual work programmes setting out, in particular, actions to be taken and an indicative allocation of financial resources. The actions are to come under the four objectives and 23 thematic priorities identified in Annex I to the Regulation.

The full version of Annex 1 after adoption of the 2020 work programme will be available only in English and accessible at https://ec.europa.eu/health/funding/programme_en

The overall budgetary envelope for 2020 amounts to **EUR 65 361 158**.

<table>
<thead>
<tr>
<th>Allocation of resources for 2020:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- grants (direct management): EUR 37 155 000</td>
</tr>
<tr>
<td>o operating grants: EUR 5 000 000</td>
</tr>
<tr>
<td>o action grants: EUR 32 155 000 (direct management)</td>
</tr>
<tr>
<td>- prizes : EUR 400 000</td>
</tr>
<tr>
<td>- procurement (direct management): EUR 15 565 158</td>
</tr>
<tr>
<td>- other actions: EUR 12 241 000</td>
</tr>
</tbody>
</table>

The 2020 work programme is based on the following thematic priority areas, while addressing ‘health inequalities’ as a cross-cutting issue:

- promote health, prevent diseases and foster supportive environments for healthy lifestyles;
- protect Union citizens from serious cross-border health threats;
- contribute to innovative, efficient and sustainable health systems; and
- facilitate access to better and safer healthcare for Union citizens.

Within these areas, the following topics are important for the 2020 programme:

1.4 Chronic diseases, including cancer, age-related diseases and neurodegenerative diseases
1.5 Tobacco legislation
1.6 Health information and knowledge system to contribute to evidence-based decision-making
2.2 Capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries
2.3 Implementation of Union legislation on communicable diseases and other health threats, including those caused by biological and chemical incidents, environment and climate change

2.4 Health information and knowledge system to contribute to evidence-based decision-making

3.1 Health technology assessment (HTA)

3.2 Innovation and e-health

3.4 Setting up a mechanism for pooling expertise at Union level

3.6 Implementation of Union legislation in the field of medical devices, medicinal products and cross-border healthcare

3.7 Health information and knowledge system, including support for the scientific committees set up in accordance with Commission Decision 2008/721/EC

3.1 Health technology assessment (HTA)

3.2 Innovation and e-health

3.4 Setting up a mechanism for pooling expertise at Union level

3.6 Implementation of Union legislation in the field of medical devices, medicinal products and cross-border healthcare

3.7 Health information and knowledge system, including support for the scientific committees set up in accordance with Commission Decision 2008/721/EC

3.1 Health technology assessment (HTA)

3.2 Innovation and e-health

3.4 Setting up a mechanism for pooling expertise at Union level

3.6 Implementation of Union legislation in the field of medical devices, medicinal products and cross-border healthcare

3.7 Health information and knowledge system, including support for the scientific committees set up in accordance with Commission Decision 2008/721/EC

4.1 European reference networks (ERNs)

4.2 Rare diseases

4.3 Patient safety and quality of healthcare

4.4 Measures to prevent antimicrobial resistance (AMR) and control healthcare-associated infections

4.5 Implementation of Union legislation in the fields of tissues and cells, blood, organs

4.6 Health information and knowledge system to contribute to evidence-based decision-making.

The **expected results** of the work programme include:

- enhanced knowledge base for the conception and implementation of reforms on retention policies, medical deserts and task-shifting related to the health workforce;
- knowledge-sharing and discussion on public procurement in the healthcare sector;
- the exchange and adoption of best practices in various areas of health;
- increased vaccination uptake among disadvantaged groups and migrants;
- an NGO contribution to achieving the objectives of the EU health programme;
- enhanced understanding of properties and regulatory implications of novel tobacco products and e-cigarettes;
- a GDPR-compliant data governance model and code of conduct for health(care)-related data;

**Actions** proposed for funding:

**Grants**

**Operating grants**

- Financial contribution to the functioning of non-governmental bodies
Action grants

Action grants following a call for proposal:

Call for projects

➢ support for health workforce reforms;
➢ healthcare procurement in the EU;
➢ support for health investment;
➢ support for the implementation of best practices in the area of mental health;
➢ increased access to vaccination for disadvantaged groups, difficult-to-reach groups and migrants;
➢ stakeholder activities to support strengthened cooperation against vaccine-preventable diseases.

Action grants directly awarded

Direct grants with international organisations:

➢ Council of Europe – contribution to work of European Pharmacopoeia;
➢ OECD – health information support for prioritisation of best practice implementation;
➢ OECD – support for development and implementation of patient-reported measures;
➢ OECD – pharmaceutical innovation and access to medicines.

Grants for actions co-financed with Member State authorities / joint actions:

➢ strengthening cooperation on tobacco control between interested Member States and the Commission;
➢ support for Member States’ implementation of best practices in the area of mental health;
➢ increasing the capacity of national focal points to provide guidance, information and assistance on the implementation of the ESF+ health strand and possible support for health-related actions under other EU funding instruments;
➢ ironing out differences in national GDPR implementation in the health sector – development of a code of conduct for data processing;
➢ EU HTA cooperation, with a focus on joint clinical assessments (2021-2024).

Other direct grants:

➢ direct grants to presidency holders for two conferences.

Prizes

➢ EU Health Award for NGOs, cities and schools.

Procurement

➢ enhancing implementation of Cross-Border Healthcare Directive to uphold patients’ rights;
future-proofing pharmaceutical legislation – study on medicine shortages;
Health Policy Platform operation;
Scientific Committee on Health, Environmental and Emerging Risks (SCHEER);
feasibility study – ‘monograph’ system and other potential alternatives for the environmental risk assessment of veterinary medicinal products;
dissemination of the results of the health programme;
remuneration of expert evaluators and reviewers;
horizontal and policy-related communication activities;
follow-up to evaluation of orphan and paediatric legislation;
ex post evaluation of third health programme;
maintenance and development of the current Eudamed 2;
development of the future Eudamed;
IT audits of Eudamed;
support for expert groups in the field of (public) health;
IT systems and services in support of public health policies;
call for a framework contract with reopening of competition with independent assessment and evaluation bodies;
extpert panel on effective ways of investing in HTA;
support for the implementation of health systems performance assessment at national level;
support for implementation of the Tobacco Products Directive (TPD) – Eurobarometer;
support for TPD implementation – operation of technical group;
support for TPD implementation – better use of IT data;
clinical patient management system – licensing and storage costs;
ERN members – services from independent assessment and evaluation bodies;
study to support action to address shortcomings in EU legislation on blood, tissues and cells;
pharmaceutical framework – studies, conferences and working groups;
development of the clinical patient management system.

Other
administrative agreement with the (Joint Research Centre)JRC – tobacco ingredients, e-cigarettes and security features;
audits of national e-health contact points wishing to participate in the cross-border exchange of health data;
coordination of rare-disease registers for European reference networks (ERNs);
e-training, e-learning and education strategy for ERNs;
- clinical trial portal and database;
- administrative agreement with JRC – healthcare quality, cancer, rare-disease registration, health promotion and prevention of non-communicable diseases;
- contribution to survey on gender-based violence;
- technical, scientific and related logistical support on medical devices (JRC);
- special indemnities for the expert panel on effective ways of investing in health;
- medicinal products for human use, clinical trials for human medicines, substances of human origin – reimbursement of experts’ expenses;
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and International Pharmaceutical Regulators Programme;
- EU Health Award and Health Policy Platform – meetings, expenses and materials;
- International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) and VICH outreach forum (VOF);
- assessment of notified bodies in medical devices field – reimbursement of experts’ expenses;
- organisation and management of Medical Device Coordination Group meetings (DG GROW);
- annual membership of the European Observatory on Health Systems; and
- joint audit programme on inspections for mutual recognition agreement on good manufacturing practices inspection.